Former CEO of Novartis-Sandoz (South Africa) to Lead AAT Research’s Global Expansion
AAT Research, a research firm that designs and develops quality medical solutions in the neuroscience space, today announced that it has appointed pharmaceutical and medical industry veteran Wolfgang Storf as its new chief executive officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160406005565/en/
Mr Storf brings more than 20 years of experience in the industry with a successful record of entering new markets, providing strategic direction and boosting growth.
Prior to joining AAT, he was chief strategy officer with the MS Pharma Group. He was also CEO of Novartis-Sandoz in South Africa and held other senior management positions with Novartis-Sandoz, Apotex and Johnson & Johnson in different regions of the world. Mr Storf is a seasoned senior executive with proven global strategic and execution leadership experience – covering both commercial and technical operations as well R&D responsibility inside multinational and private businesses in the pharmaceutical and medical industry. He also has experience in post-merger integration programs in both branded / un-branded markets.
“I am delighted to take over as CEO at this important stage of AAT’s growth, and I’m looking forward to working with the executive team and the board to help the company realise its full potential, enter new markets and establish our products as leading therapies and services for patients and medical professionals respectively,” Mr Storf said.
AAT Research’s Founder and Chief Scientific Officer, Dr Adrian Attard Trevsisan, said: “We have come a long way from a small one-room setup. As the company continues to grow and increase its international footprint, we felt the need to bring in a senior executive who has extensive international experience in the pharmaceutical and medical industries.”
“The board of directors and I are extremely pleased that Wolfgang has joined the company and he will be a determining factor in the internationalisation of AAT in the coming months. I will be taking on the role of Chief Scientific Officer and Director of Product, focusing on research, innovation and product development,” Dr Attard Trevisan added.
About AAT Research
The AAT Research group of companies researches, designs, develops and manufactures quality medical solutions. With regulatory and quality systems in place and various international accreditations to its name, the group aims to lead innovation in the neurosciences field. AAT’s purpose is to improve people’s lives though innovation in the field of neuroscience and medical technology and our mission is to develop quality medical devices and cloud-based services to help improve the lives of those with neurologically-based conditions such as autism, epilepsy, depression and anxiety. For more information visit: http://www.aatrl.com .
Tel: +356 21330588
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
INGERSOLL-RAND22.1.2018 12:32 | pressemeddelelse
Ingersoll Rand Announces Acquisition of ICS Group Holdings Limited, a Leading European Temperature Control and HVAC Solutions Provider
THE-GENEVA-ASSOCIATION22.1.2018 11:02 | pressemeddelelse
The Geneva Association: Insurance Industry Taking Action in Addressing Climate Change, Although External Hurdles Remain
DIGITAL-ELEMENT22.1.2018 10:05 | pressemeddelelse
Yonnic GmbH Enriches Targeting for Clients with Digital Element’s IP Geolocation Data
PA-VERTEX22.1.2018 09:55 | pressemeddelelse
Vertex Hires Regional Leader to Expand European Presence
ALKEMICS22.1.2018 09:02 | pressemeddelelse
Alkemics to Power productDNA:Hub – an Industry-Led Service to Help Retailers and Suppliers Share Product Data and Images
OCTAPHARMA-AG22.1.2018 09:02 | pressemeddelelse
Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum